Find clinical trials

This is an extension study for patients with Hereditary Angioedema who participated in the STAR-0215-301 study.

A study to investigate the safety and efficacy of GSK4532990 compared with placebo in adult participants aged 18 to 70 years with alcohol-related liver disease.

We have selected two potential anti-Epstein-Barr virus therapies (spironolactone and famciclovir) to test in an innovative multi-stage, multi-arm trial in order to identify the best treatment for progressive MS. Treatments will be compared to dummy-treatment.

The purpose of this study is to find out if a new drug, called IDRX-42 (also known as GSK6042981), is effective in treating adults with a type of cancer called Gastrointestinal Stromal Tumors (GIST) when compared to another drug named sunitinib. The study will see if IDRX-42 works well and is safe for participants whose GIST has spread or cannot be surgically removed, and who have already taken the drug imatinib.

The purpose of this study is to find out if a new drug, called IDRX-42 (also known as GSK6042981), is effective in treating adults with a type of cancer called Gastrointestinal Stromal Tumors (GIST) when compared to another drug named sunitinib. The study will see if IDRX-42 works well and is safe for participants whose GIST has spread or cannot be surgically removed, and who have already taken the drug imatinib. Participants whose disease worsens after receiving sunitinib in this study may cross over to receive GSK6042981, at investigator's discretion and if additional eligibility criteria are met.

The STRIKE clinical trial at the Alfred Hospital tests whether the medication infliximab can reduce lung inflammation in people with advanced silicosis from artificial stone exposure. This study offers hope for a potential treatment for silicosis, a progressive lung disease that currently has no approved therapy.